Literature DB >> 11220371

Secretory meningiomas: clinical and immunohistochemical observations.

R Buhl1, H H Hugo, Z Mihajlovic, H M Mehdorn.   

Abstract

OBJECTIVE: Secretory meningiomas are a rare histological subtype of these benign intracranial tumors. Few reports have been published regarding their tendency to develop peritumoral edema.
METHODS: Between July 1994 and February 1999, 11 patients with secretory meningiomas underwent operations in the Department of Neurosurgery, University of Kiel, Kiel, Germany. The clinical notes and radiological data (computed tomographic and magnetic resonance imaging scans) were reviewed. Immunohistochemistry was used to examine the expression of carcinoembryonic antigen and epithelial membrane antigen as well as progesterone and estrogen receptors.
RESULTS: Secretory meningiomas were found in 11 (5%) of 214 patients with intracranial meningiomas who were operated on in that period. All 11 patients were women. These patients' mean age was 65 years (range, 51-87 yr). The localization of these tumors was at the convexity in seven patients, at the sphenoid ridge in two patients, and in the olfactory groove and petroclival region in one patient each. Two meningiomas had no edema surrounding them, two meningiomas had a small amount of edema, two had moderate edema, and five had severe edema. No recurrences were observed during the mean follow-up period of 26 months (range, 8-65 mo). Immunohistochemically, all tumors contained pseudopsammoma bodies and reacted with epithelial membrane antigen and carcinoembryonic antigen. The MIB-1 antibody staining index showed a mean of 2% (range, 0-7%).
CONCLUSION: Secretory meningiomas are rare tumors, and they are mainly localized at the frontal convexity and the sphenoid ridge. They are surrounded by more edema than usual. The preponderance of female patients with this presentation is striking. The expression of carcinoembryonic antigen and epithelial membrane antigen is a characteristic feature of secretory meningiomas. These meningiomas are also positive for progesterone receptors, which has been shown to be a good prognostic factor.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11220371     DOI: 10.1097/00006123-200102000-00008

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  6 in total

1.  Clinical features, surgical management, and prognostic factors of secretory meningiomas: a single-center case series of 149 patients.

Authors:  Xiaogang Tao; Kun Wang; Jinqian Dong; Zonggang Hou; Zhen Wu; Junting Zhang; Baiyun Liu
Journal:  J Neurooncol       Date:  2017-11-15       Impact factor: 4.130

2.  Secretory meningioma: immunohistochemical findings and evaluation of mast cell infiltration.

Authors:  Wuttipong Tirakotai; Hans-Dieter Mennel; Ilhan Celik; Dieter Hellwig; Helmut Bertalanffy; Thomas Riegel
Journal:  Neurosurg Rev       Date:  2005-07-12       Impact factor: 3.042

3.  Secretory meningiomas: clinical, radiological and pathological findings in 70 consecutive cases at one institution.

Authors:  Dai-Jun Wang; Qing Xie; Ye Gong; Yin Wang; Hai-Xia Cheng; Ying Mao; Ping Zhong; Feng-Ping Huang; Kang Zheng; Yong-Fei Wang; Wei-Min Bao; Bo-Jie Yang; Hong Chen; Li-Qian Xie; Ming-Zhe Zheng; Hai-Liang Tang; Hong-Da Zhu; Xian-Cheng Chen; Liang-Fu Zhou
Journal:  Int J Clin Exp Pathol       Date:  2013-02-15

Review 4.  Secretory meningiomas.

Authors:  Nagihan Colakoğlu; Eren Demirtaş; Nezih Oktar; Nilgün Yüntem; Sertaç Islekel; Nurcan Ozdamar
Journal:  J Neurooncol       Date:  2003-05       Impact factor: 4.130

5.  Diagnostic impact of ornithine decarboxylase in meningiomas.

Authors:  Werner Stenzel; Gabriele Röhn; Hrvoje Miletic; Herbert Radner; Martina Deckert; Ralf-Ingo Ernestus
Journal:  J Neurooncol       Date:  2004-01       Impact factor: 4.130

6.  Secretory meningiomas: a benign subgroup causing life-threatening complications.

Authors:  Jan Regelsberger; Christian Hagel; Pedram Emami; Thorsten Ries; Oliver Heese; Manfred Westphal
Journal:  Neuro Oncol       Date:  2009-12       Impact factor: 12.300

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.